Studies in HCV patients indicated a higher incidence of liver‐related adverse events during IFNλ versus IFNα treatment, but lower haematological abnormalities such as neutropenia or thrombocytopenia and fewer influenza‐like symptoms such as pyrexia, chills or pain in patients treated with IFNλ compared to IFNα, in line with lower direct immunomodulatory effect of IFNλ (Muir et al, 2014). The gene discussed is IFNA1; the disease is Thrombocytopenia.